Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Thomas Theodor Werner Seufferlein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3259-0810; OpenAlex author ID A5062163674, A5069391107, A5111602852. Sources: OpenAlex.

Their work

Papers
77 (first author 6, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
203
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 2 papers · 2014: 6 papers · 2015: 2 papers · 2016: 6 papers · 2017: 3 papers · 2018: 4 papers · 2019: 6 papers · 2020: 5 papers · 2021: 8 papers · 2022: 4 papers · 2023: 6 papers · 2024: 3 papers · 2025: 10 papers · 2026: 8 papers

Papers 50 of 77

  1. DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
  2. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  4. A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-48584-2↗
  5. Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
  6. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  7. An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Co-author DOI 10.1186/s12943-025-02541-1↗
  8. Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach. Co-author DOI 10.14740/gr2132↗
  9. Organoid-based precision medicine in pancreatic cancer. Co-author DOI 10.1002/ueg2.12701↗
  10. Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. Co-author DOI 10.1002/ueg2.12773↗
  11. Toward a new standard: Sequential multi-agent neoadjuvant chemotherapy in resectable pancreatic cancer. First author DOI 10.1016/j.ccell.2025.10.003↗
  12. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(25)00261-2↗
  13. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  14. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Co-author DOI 10.1101/2025.04.24.650216↗
  15. Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines. Co-author DOI 10.1136/jitc-2024-010579↗
  16. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Last author DOI 10.1186/s12943-025-02406-7↗
  17. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  18. Personalizing Chemotherapy in Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco-25-01786↗
  19. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing. Co-author DOI 10.1038/s41598-024-60107-5↗
  20. Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry. Co-author DOI 10.1186/s12885-024-12995-z↗
  21. Mistletoe and Pancreatic Cancer. Co-author DOI 10.3238/arztebl.m2024.0099↗
  22. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  23. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  24. [Exocrine pancreatic cancer - what is new in the update of the S3 guideline?] Co-author DOI 10.1055/a-1932-0156↗
  25. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
  26. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… First author DOI 10.1186/s12885-023-11377-1↗
  27. Pancreatic Cancer: BRCA Targeted Therapy and Beyond. Co-author DOI 10.3390/cancers15112955↗
  28. [Future concepts for neoadjuvant and adjuvant treatment of (resectable) pancreatic cancer]. Co-author DOI 10.1007/s00104-022-01623-w↗
  29. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  30. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice. Last author DOI 10.1159/000527692↗
  31. Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14041074↗
  32. Systemic Therapy for Metastatic Pancreatic Cancer. First author DOI 10.1007/s11864-021-00895-4↗
  33. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Co-author DOI 10.1016/j.ejca.2020.12.029↗
  34. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  35. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Co-author DOI 10.1136/gutjnl-2019-319984↗
  36. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2633↗
  37. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Co-author DOI 10.3390/cancers13112539↗
  38. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers13133145↗
  39. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Co-author DOI 10.3390/cancers13194844↗
  40. A feedback-loop between telomerase activity and stemness factors regulates PDAC stem cells Co-author DOI 10.1101/2020.11.02.361931↗
  41. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  42. Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pan… Co-author DOI 10.3390/cancers12113130↗
  43. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Co-author DOI 10.3390/cells9092110↗
  44. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms21093345↗
  45. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Co-author DOI 10.1016/j.ctrv.2019.05.007↗
  46. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Co-author DOI 10.1038/s41388-019-0803-9↗
  47. Systemic treatment of pancreatic cancer revisited. First author DOI 10.1053/j.seminoncol.2018.12.003↗
  48. MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Co-author DOI 10.1155/2019/8475389↗
  49. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Co-author DOI 10.21037/tgh.2019.03.05↗
  50. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Last author DOI 10.7150/thno.29247↗

Closest collaborators

The 25 strongest of 203 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander Kleger · 28 shared papers, 2014–2026 · strength 3.97
  2. Thomas Jens Ettrich · 19 shared papers, 2014–2026 · strength 2.59
  3. Lukas Perkhofer · 20 shared papers, 2014–2026 · strength 2.12
  4. Johann Gout · 12 shared papers, 2019–2026 · strength 1.81
  5. Élodie Roger · 10 shared papers, 2020–2026 · strength 1.56
  6. Frank Arnold · 10 shared papers, 2020–2026 · strength 1.30
  7. Tim Eiseler · 8 shared papers, 2014–2026 · strength 1.28
  8. Anton Lahusen · 5 shared papers, 2024–2026 · strength 1.08
  9. Alica K. Beutel · 7 shared papers, 2019–2025 · strength 1.08
  10. Patrick Christian Hermann · 10 shared papers, 2016–2026 · strength 1.05
  11. Karolin Walter · 8 shared papers, 2016–2026 · strength 0.80
  12. Dharini Srinivasan · 4 shared papers, 2025–2026 · strength 0.78
  13. Bruno Sáinz · 7 shared papers, 2019–2026 · strength 0.73
  14. Michael Karl Melzer · 4 shared papers, 2020–2026 · strength 0.71
  15. Andrea Tannapfel · 6 shared papers, 2014–2025 · strength 0.71
  16. Christopher J. Halbrook · 3 shared papers, 2025–2026 · strength 0.62
  17. Chantal Allgöwer · 3 shared papers, 2026 · strength 0.62
  18. Hans Armin Kestler · 5 shared papers, 2021–2025 · strength 0.61
  19. Marko Kornmann · 5 shared papers, 2018–2025 · strength 0.54
  20. Anke Reinacher‐Schick · 5 shared papers, 2018–2023 · strength 0.54
  21. Jens Thomas Siveke · 4 shared papers, 2019–2025 · strength 0.52
  22. Waldemar H. Uhl · 5 shared papers, 2014–2024 · strength 0.51
  23. Christoph W. Michalski · 2 shared papers, 2022–2025 · strength 0.51
  24. Albrecht Stenzinger · 3 shared papers, 2023–2026 · strength 0.51
  25. Angelika M. R. Kestler · 2 shared papers, 2023 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.